NCT00392717

Regulation of Lipoprotein Metabolism in Obese Men

Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in Visceral Obesity

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 48 (planned)
• Sponsor: The University of Western Australia · Academic / Other
• Sex: Male
• Age: 20 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Visceral obesity is strongly associated with dyslipidaemia (hypertriglyceridaemia, low HDL-cholesterol and mildly elevated LDL-cholesterol) and insulin resistance, key characteristics of metabolic syndrome (MetS). Recent evidence has clearly established that the risk of CVD is increased in subjects with the MetS. The precise reason for this remains unclear, but appears to be closely related with dyslipidaemia. Effective management of dyslipidaemia is important to reduce the risk of CVD in these subjects. Hypothesis: Inhibition of hepatic cholesterol synthesis by statins and triglyceride synthesis by fish oils improve lipoprotein metabolism in visceral obese men.

Detailed description

The study employed a factorial study design, stable isotopy and mathematical modelling to examine the independent and combined effects of decreasing cholesterol substrate availability with atorvastatin and decreasing triglyceride substrate availability with fish oils on lipoprotien kinetics (apoB, apoA, apoC-III and chylomicron remnants) in insulin-resistant men with visceral obesity.

Conditions

• Obesity
• Dyslipidemia
• Insulin Resistance

Interventions

Type	Name	Description
DRUG	Atorvastatin
DRUG	Fish oils

Timeline

• Start date: 1998-02-01
• Completion: 2002-03-01
• First posted: 2006-10-26
• Last updated: 2006-10-26

Locations

1 site across 1 country: Australia